Symbiotec starts FY27 with operating margin above healthcare peer median
Consolidated profit was driven mainly by operations, while management outlined a customer-backed 600 KL CDMO expansion and new-business revenue within 6–12 months.
Filed 21 Sep 2026, 18:44 IST · after market close · Symbiotec Pharmalab Ltd (SYMBIOTEC)
Key takeaways
- Symbiotec reported consolidated net profit of Rs 14.06 cr in Q1FY27, with other income at only Rs 0.34 cr.
- Its 20.72% operating margin was 0.24 percentage points above the 20.48% median for 113 reported healthcare peers.
- Management said a 600 KL CDMO capacity addition is backed by a customer agreement, while new-business revenue is expected to start in 6–12 months.
Price around the results
Operating profit cleared the healthcare peer benchmark
Symbiotec's consolidated operating profit of Rs 45.20 cr translated into a 20.72% operating margin, 0.24 percentage points above the 20.48% median for 113 healthcare peers that had reported the quarter. This places the company slightly above the sector midpoint, rather than materially ahead of it.
Depreciation and interest reduced operating profit's conversion into PBT
Interest of Rs 6.18 cr and depreciation of Rs 21.82 cr reduced operating profit of Rs 45.20 cr to profit before tax of Rs 17.53 cr. Other income was only Rs 0.34 cr, so reported profit was not reliant on a large non-operating contribution; the consolidated tax rate was 19.8%.
Management points to new businesses and CDMO capacity
Management said revenue from new businesses is expected to commence in the next 6–12 months. The company also said it plans to initiate 600 KL of CDMO capacity backed by a customer agreement, providing the clearest disclosed growth actions beyond the current quarter.
Results were filed after market close
The consolidated results were filed after market close on 21 September 2026. The available quarter disclosure provides no subsequent stock reaction to assess against the company's past results.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹218 cr |
| Other income | ₹0 cr |
| Expenses | ₹173 cr |
| Operating profit | ₹45 cr |
| Operating margin (%) | 20.72% |
| Interest | ₹6 cr |
| Depreciation | ₹22 cr |
| Profit before tax | ₹18 cr |
| Tax | ₹3 cr |
| Net profit | ₹14 cr |
| EPS (₹) | ₹2.24 |
Operating margin of 20.72% compares with a Healthcare sector median of 20.48% across 113 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- Revenue from new businesses is expected to commence in the next 6–12 months.
Expansion
- The company plans to initiate 600 KL of CDMO capacity backed by a customer agreement.
What to watch
- Whether operating margin holds around 20.72% in the next reported quarter.
- Whether revenue from new businesses starts within management's stated 6–12-month window.
- Progress on the customer-backed 600 KL CDMO capacity initiative.